DCGI approves psoriasis injection for 'restricted emergency use' to treat COVID-19 patients
Drugs Controller General of India approved monoclonal antibody injection Itolizumab for limited use to treat moderate to severe cases of COVID-19.
New Delhi: India's drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr VG Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of 'cytokine' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.
"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.
Written informed consent of each patient is required before the use of this drug, he said.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
Coronavirus Updates: Bihar aims to conduct over 1 lakh COVID-19 tests daily after PM says state lags behind in testing
Coronavirus LIVE Updates: Bihar chief minister Nitish Kumar Tuesday told Prime Minister Narendra Modi that the state plans to raise testing rate for COVID-19 to over one lakh per day.
As COVID-19 is a respiratory infection that affects the lungs, dysphagia is also common among the patients who were not ventilated.
Epidemiological studies will begin in Wuhan to identify the potential source of early cases of COVID-19, said WHO Director-General Tedros Adhanom Ghebreyesus